医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2014年
11期
20-21
,共2页
丙泊酚%布托啡诺%无痛人流%静脉全麻
丙泊酚%佈託啡諾%無痛人流%靜脈全痳
병박분%포탁배낙%무통인류%정맥전마
Propofol%Butorphanol%Painless abortion surgery%Intravenous anesthesia
目的:探讨丙泊酚复合布托啡诺用于无痛人流手术的麻醉效果和安全性。方法门诊无痛人流手术孕妇50例,随机分为丙泊酚组(P组)和布托啡诺组(B组),每组25例。P组静注丙泊酚3mg?kg-1,B组静注布托啡诺1mg+丙泊酚2.5mg·kg-1,待孕妇意识消失后开始手术,术中若体动影响手术则追加丙泊酚30mg。记录麻醉前(T0)、麻醉后2min(T1),4min(T2)和手术结束时(T3)的MAP、HR和SpO2;记录手术时间、苏醒时间、出院时间、丙泊酚用量、麻醉效果评级、不良反应(术中呼吸抑制、术后头晕、恶心呕吐)的发生情况和术后下腹痛VAS评分。结果丙泊酚用量B组低于P组(P<0.05);组内MAP和HR比较,两组T1、T2高于T0(P<0.05);组间MAP和HR比较,B组在T1、T2低于P组(P<0.05);两组SpO2组内组间比较差异均无统计学意义(P>0.05);麻醉效果和下腹痛VAS评分B组优于P组(P<0.05),两组不良反应比较差异无统计学意义(P>0.05)。结论丙泊酚复合布托啡诺用于无痛人流手术可获得满意的麻醉效果,减少丙泊酚用量,减轻术后下腹疼痛,不良反应发生率低。
目的:探討丙泊酚複閤佈託啡諾用于無痛人流手術的痳醉效果和安全性。方法門診無痛人流手術孕婦50例,隨機分為丙泊酚組(P組)和佈託啡諾組(B組),每組25例。P組靜註丙泊酚3mg?kg-1,B組靜註佈託啡諾1mg+丙泊酚2.5mg·kg-1,待孕婦意識消失後開始手術,術中若體動影響手術則追加丙泊酚30mg。記錄痳醉前(T0)、痳醉後2min(T1),4min(T2)和手術結束時(T3)的MAP、HR和SpO2;記錄手術時間、囌醒時間、齣院時間、丙泊酚用量、痳醉效果評級、不良反應(術中呼吸抑製、術後頭暈、噁心嘔吐)的髮生情況和術後下腹痛VAS評分。結果丙泊酚用量B組低于P組(P<0.05);組內MAP和HR比較,兩組T1、T2高于T0(P<0.05);組間MAP和HR比較,B組在T1、T2低于P組(P<0.05);兩組SpO2組內組間比較差異均無統計學意義(P>0.05);痳醉效果和下腹痛VAS評分B組優于P組(P<0.05),兩組不良反應比較差異無統計學意義(P>0.05)。結論丙泊酚複閤佈託啡諾用于無痛人流手術可穫得滿意的痳醉效果,減少丙泊酚用量,減輕術後下腹疼痛,不良反應髮生率低。
목적:탐토병박분복합포탁배낙용우무통인류수술적마취효과화안전성。방법문진무통인류수술잉부50례,수궤분위병박분조(P조)화포탁배낙조(B조),매조25례。P조정주병박분3mg?kg-1,B조정주포탁배낙1mg+병박분2.5mg·kg-1,대잉부의식소실후개시수술,술중약체동영향수술칙추가병박분30mg。기록마취전(T0)、마취후2min(T1),4min(T2)화수술결속시(T3)적MAP、HR화SpO2;기록수술시간、소성시간、출원시간、병박분용량、마취효과평급、불량반응(술중호흡억제、술후두훈、악심구토)적발생정황화술후하복통VAS평분。결과병박분용량B조저우P조(P<0.05);조내MAP화HR비교,량조T1、T2고우T0(P<0.05);조간MAP화HR비교,B조재T1、T2저우P조(P<0.05);량조SpO2조내조간비교차이균무통계학의의(P>0.05);마취효과화하복통VAS평분B조우우P조(P<0.05),량조불량반응비교차이무통계학의의(P>0.05)。결론병박분복합포탁배낙용우무통인류수술가획득만의적마취효과,감소병박분용량,감경술후하복동통,불량반응발생솔저。
Objective:To evaluate the anesthetic effect and safety of propofol combined with butorphanol on painless abortion surgery.Methods:50 pregnant women scheduled to undergo painless abortion surgery in outpatient department were randomly divided into two groups (n=25 each): the propofol group (group P) and the butorphanol group (group B).The pregnant women in group P received propofol 3 mg kg-1 i.v.,while received butorphanol 1 mg and propofol 2.5 mg.kg-1 in group B. The operation was begun after pregnant women fal asleep. Propofol 30 mg was administered i.v.if the operation was disturbed by the movement of pregnant women.MAP, HR and SpO2 were recorded before injection, at 2,4 min after injection and the end of operation. The time of operation, opening eyes, and leaving hospital were recorded. The dosage of propofol, anesthesia effect rating, incidence of adverse reactions(including hypoxia, dizzy, nausea and vomiting)and VAS were recorded.Results:Dosage of propofol and VAS were reduced in group B compared with group P (P<0.05). Anesthesia effect rating was better in group B compared with group P (P<0.05). MAP and HR at 2,4 min after injection were reduced in group B compared with group P (P<0.05), while were increased after injection in two groups(P<0.05). No differences were found with SpO2 and adverse reactions among two groups (P<0.05).Conclusion:Propofol combined with butorphanol used in painless abortion surgery can achieve good anesthetic effect, while reducing dosage of propofol, postoperative pain and incidence of adverse reactions.